Canadian cannabis firm Organigram's Q1 net revenue jumps 49%

Organigram Global

10/02/2026 11:08

Overview

Canada cannabis firm's fiscal Q1 net revenue rose 49% yr/yr but missed analyst expectations

Adjusted EBITDA for fiscal Q1 increased significantly, driven by higher recreational and international revenue

Company achieved genetic screening breakthrough for powdery mildew resistance, improving yield stability

Outlook

Organigram expects continued growth in international sales throughout Fiscal 2026

Company is preparing for EU-GMP certification for its Moncton facility

Result Drivers

MOTIF ACQUISITION - Net revenue growth driven by contributions from Motif Labs acquisition and increased international sales

GROSS MARGIN IMPROVEMENT - Adjusted gross margin rose due to operational efficiencies, higher flower yields, and Motif integration synergies

GENETIC BREAKTHROUGH - Achieved genetic screening breakthrough for powdery mildew resistance, enhancing yield stability and reducing costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
C$63.54 mln
C$73.15 mln (5 Analysts)
Q1 Gross Revenue
C$97.30 mln
Q1 Net Income
C$19.97 mln
Q1 Adjusted EBITDA
C$5.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Organigram Global Inc is C$3.25, about 49.8% above its February 9 closing price of C$2.17

Press Release: ID:nBw9TxzBHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)